(P134) An Overview of the First One Hundred Patients Treated With a New Cutting-Edge, Frameless, Image-Guided, Stereotactic Radiosurgery System

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

The Edge RS system possesses the high-accuracy localization and delivery requirements for safely treating patients with tumors in the CNS and other sites using SRS/SBRT-based techniques.

Ning Wen, PhD, Karen Chin-Snyder, MS, Haisen Li, PhD, Kwang Song, PhD, James Gordon, PhD, Indrin Chetty, PhD, Munther Ajlouni, MD, Farzan Siddiqui, MD, Benjamin Movsas, MD, Salim Siddiqui, MD; Henry Ford Health System

PURPOSE: To summarize our experience with treating our first 100 patients treated using an innovative linear accelerator (Linac)-based stereotactic radiosurgery (SRS) system.

MATERIALS AND METHODS: A novel platform for Linac-based SRS treatment, the Edge (Varian Medical Systems, Palo Alto, CA), offers multiple imaging modalities for treatment localization, including an optical surface monitoring system (OSMS) for surface tracking, 2.5 MV portal imaging, triggered monoscopic kV imaging to track intrafractional motion, four-dimensional (4D) cone-beam computed tomography (CBCT) to evaluate tumor motion offline, extended CBCT images by stitching multiple CBCT scans together, and a Calypso/Varian electromagnetic beacon-based tracking system. The new robotics couch supports six-degrees-of-freedom corrections from multiple imaging modalities for precise patient setup. We have comprehensively commissioned this system and have worked out a clinical workflow for treating patients with different cancer types.

RESULTS: The breakdown of tumor sites treated with SRS/stereotactic body radiation treatment (SBRT) techniques was central nervous system (CNS) (31%), lung (29%), spine (23%), GI (9%), adrenal glands (7%), and head and neck (1%). The treatment techniques used were as follows: volumetric-modulated arc therapy (39%), intensity-modulated RT (35%), dynamic conformal arc (21%), and three-dimensional (3D) conformal RT (5%). For CNS sites except glioblastoma multiforme (GBM), the dose was delivered in a single fraction (range: 10–18 Gy), and the target volume (TV) ranged from 0.10 cc (acoustic neuroma) to 21.05 cc (metastasis). GBM patients were treated with four fractions using the simultaneous integrated boost technique (32 Gy to the enhanced lesion and 24 Gy to the edema). Volume sizes of the enhanced lesions ranged from 7.86 cc to 128.05 cc. All lung patients were treated with 48 Gy in four fractions, except three recurrent treatments with 36 Gy in three fractions. Median TV volume was 36.53 cc (range: 4.09–85.12 cc). V20 for the total lungs was 3.59% on average (range: 0.50%–7.37%). All T-spine metastases were treated in a single fraction, with the dose ranging from 14 Gy (primary: multiple myeloma) to 18 Gy (all other primary diagnoses). The median TV volume was 43.82 cc (range: 11.80–121.77 cc). The maximum dose to 0.03 cc of the spinal cord was 10.86 cc (range: 7.90–15.15 cc). The clinical flow designed for each treatment site using multiple imaging modalities and treatment techniques will be presented. The setup time, imaging fusion time, and beam on time will be categorized according to the treatment site.

CONCLUSION: The Edge RS system possesses the high-accuracy localization and delivery requirements for safely treating patients with tumors in the CNS and other sites using SRS/SBRT-based techniques.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Related Content